Schulhoff & CO Inc Avadel Pharmaceuticals PLC Transaction History
Schulhoff & CO Inc
- $222 Million
- Q3 2024
A detailed history of Schulhoff & CO Inc transactions in Avadel Pharmaceuticals PLC stock. As of the latest transaction made, Schulhoff & CO Inc holds 137,000 shares of AVDL stock, worth $1.5 Million. This represents 0.81% of its overall portfolio holdings.
Number of Shares
137,000
Previous 137,000
-0.0%
Holding current value
$1.5 Million
Previous $1.93 Million
6.7%
% of portfolio
0.81%
Previous 0.93%
Shares
3 transactions
Others Institutions Holding AVDL
# of Institutions
8Shares Held
1.07MCall Options Held
0Put Options Held
0-
Knoll Capital Management, LLC Miami, FL600KShares$6.56 Million3.88% of portfolio
-
Knott David M Jr Syosset, NY332KShares$3.63 Million1.53% of portfolio
-
1620 Investment Advisors, Inc. Plymouth, MA1KShares$10,9300.01% of portfolio
-
American Portfolios Advisors Holbrook, NY500Shares$5,4650.0% of portfolio
-
American Research & Management Co.100Shares$1,0930.0% of portfolio
About AVADEL PHARMACEUTICALS PLC
- Ticker AVDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 60,581,300
- Market Cap $662M
- Description
- Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...